First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

被引：0
|
作者：
J J Ko
T K Choueiri
B I Rini
J-L Lee
N Kroeger
S Srinivas
L C Harshman
J J Knox
G A Bjarnason
M J MacKenzie
L Wood
U N Vaishampayan
N Agarwal
S K Pal
M-H Tan
S Y Rha
T Yuasa
F Donskov
A Bamias
D Y C Heng
机构：
[1] Tom Baker Cancer Center,Department of Oncology
[2] University of Calgary,Department of Urology
[3] Dana Farber Cancer Institute,Division of Oncology
[4] Cleveland Clinic Taussig Cancer Institute,Division of Oncology
[5] Asan Medical Center,Department of Medicine
[6] University of Ulsan College of Medicine,Department of Urology
[7] Universitätsmedizin Greifswald,Department of Oncology
[8] Stanford Medical Center,undefined
[9] Stanford Cancer Institute,undefined
[10] Stanford School of Medicine,undefined
[11] Princess Margaret Cancer Centre,undefined
[12] University Health Network,undefined
[13] University of Toronto,undefined
[14] Sunnybrook Odette Cancer Centre,undefined
[15] University of Toronto,undefined
[16] London Health Sciences Center,undefined
[17] Queen Elizabeth II Health Sciences Centre and Dalhousie University,undefined
[18] Karmanos Cancer Institute,undefined
[19] Wayne State University,undefined
[20] Huntsman Cancer Institute,undefined
[21] University of Utah,undefined
[22] City of Hope Comprehensive Cancer Center,undefined
[23] Medical Oncology & Experimental Therapeutics,undefined
[24] Duarte,undefined
[25] National Cancer Center,undefined
[26] Institute of Bioengineering and Nanotechnology,undefined
[27] Yonsei University Hospital,undefined
[28] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined
[29] Aarhus University Hospital,undefined
[30] Alexandra Peripheral General Hospital,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
metastatic renal cell carcinoma; targeted molecular therapy; outcomes assessment; overall survival; progression-free survival; mTOR inhibitor; VEGF inhibitor; benchmarks; international metastatic renal cell cancer database consortium;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1917 / 1922
页数：5
相关论文
共 50 条
  • [31] Attrition rates from first- to third-line therapy in HER2+metastatic breast cancer in Europe
    Hall, Peter
    Cheeseman, Sue
    Cottu, Paul
    Krebs, Markus
    Scholz, Christian
    Vallet, Maheva
    Niklas, Nicolas
    Hogg, Catherine
    Lucerna, Markus
    Collin, Simon M.
    Logue, Amanda
    Long, Grainne
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [32] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    [J]. AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [33] A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).
    Thota, Ramya
    Goff, Laura Williams
    Chan, Emily
    Berlin, Jordan
    Jones, C. Michael
    McClanahan, Pamela
    Ayers, Gregory Dan
    Cardin, Dana Backlund
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France
    Rondeau, Virginie
    Cornet, Edouard
    Moreau, Philippe
    Troussard, Xavier
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (08) : 1307 - 1313
  • [35] Implicit learning of first-, second-, and third-order transition probabilities
    Remillard, G
    Clark, JM
    [J]. JOURNAL OF EXPERIMENTAL PSYCHOLOGY-LEARNING MEMORY AND COGNITION, 2001, 27 (02) : 483 - 498
  • [36] Ciprofloxacin degradation by first-, second-, and third-generation manganese porphyrins
    Almeida Lage, Ana Luisa
    Meireles, Alexandre Moreira
    Marciano, Aline Capelao
    Ribeiro, Juliana Martins
    de Souza-Fagundes, Elaine Maria
    da Silva Martins, Dayse Carvalho
    [J]. JOURNAL OF HAZARDOUS MATERIALS, 2018, 360 : 445 - 451
  • [37] Effect of concentration gradient on the first-, second- and third-order polarizabilities
    Xu, WX
    [J]. OPTICS AND LASER TECHNOLOGY, 2002, 34 (03): : 187 - 192
  • [38] Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma
    Benjamin, David J. J.
    Lythgoe, Mark P. P.
    Rezazadeh, Arash
    [J]. BJU INTERNATIONAL, 2023, 131 (06) : 691 - 693
  • [39] Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France
    Virginie Rondeau
    Edouard Cornet
    Philippe Moreau
    Xavier Troussard
    [J]. Annals of Hematology, 2016, 95 : 1307 - 1313
  • [40] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
12345